Helus Pharma Inc. (HELP) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Helus Pharma Inc. (NASDAQ: HELP) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $10.71 (-1.83% 1D, market cap $782.5M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, HELP ranks #359 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HELP carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, COLL (Collegium Pharmaceutical Inc.) holds a B grade (72/100 RQD, P/E 12.4x, ROIC 85.0%, cap $782.3M) and AVBP (ArriVent BioPharma Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $786.5M). Among the 5-stock peer group, COLL leads on earnings multiple (12.4x) while COLL leads on capital efficiency (85.0% ROIC).
For Helus Pharma Inc. (HELP), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #359 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0.5% FCF Margin ($21.9M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
While HELP currently carries a cautious 49/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.96) and Max Pain ($11.25) forces dealer call-delta covering toward $15.91.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Helus Pharma Inc. (HELP) slipped -1.83% to $10.71, trading at 61% of its 52-week range ($3.76 – $15.15). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
https://www.marijuanamoment.net/new-bill-in-congress-would-dramatically-overhaul-how-the-federal-government-classifies-drugs-while-legalizing-marijuana/
Co-founders to step down from executive roles and continue to serve on the Board of Directors Helus Pharma board member, Mark Lawson, appointed as new independent Chair of the Board of Directors, effective immediately Th
Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health through the
Key Takeaways; Cannabis Sector Curaleaf Challenged Aurora’s Rejection of $5-Per-Share Takeover Bid Decibel Cannabis Responded to Canadian Investment Firm, Ewing Morris’s, $5 Million Share Purchase Offer Key Takeaways; Ps
2026-10-23. The following slide deck was published by Helus Pharma Inc.
Wells Fargo analyst Benjamin Burnett maintains Helus Pharma (NASDAQ:HELP) with a Overweight and raises the price target from $16 to $22.
Topline data readout from APPROACH Phase 3 study of HLP003 in development for the potential adjunctive treatment of major depressive disorder (“MDD”) on track for Q4 20261,2 HLP004 Program progressing with Phase 2 monoth
Cybin (NASDAQ:HELP) outlined plans for two late-stage mental health programs, with top-line data from its Phase III APPROACH study of HLP003 in major depressive disorder expected later in the fourth quarter of 2026. Helu
Cybin Inc. (HELP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on HELP today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for HELP. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Helus Pharma Inc. (HELP) ranks #359 by composite RQD confidence (49/100, grade D) and #388 by equity capitalization ($782.5M). Within this direct 5-issuer industry benchmark cohort, COLL leads on earnings valuation at 12.4x trailing P/E, while COLL leads on capital efficiency and profitability with 85.0% ROIC and 59.3% gross margin. COLL currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with HELP at 49/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HELP
ACTIVE
Helus Pharma Inc. | D | 49/100 | — | — | — | -1.83% | $782.5M | Benchmark Subject |
| COLL Collegium Pharmaceutical Inc. | B | 72/100 | 12.4x | 59.3% | 85.0% | +3.44% | $782.3M | /coll-vs-help → |
| AVBP ArriVent BioPharma Inc. | D- | 35/100 | — | — | -35.0% | +1.40% | $786.5M | /avbp-vs-help → |
| ARDX Ardelyx Inc. | D- | 35/100 | — | 90.3% | -32.7% | 0.00% | $772.5M | /ardx-vs-help → |
| ANNX Annexon Inc. | D- | 40/100 | — | — | -35.0% | -0.74% | $760.2M | /annx-vs-help → |
Helus Pharma Inc. (HELP) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $782.5M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-01, Helus Pharma Inc. (NASDAQ: HELP) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $10.71 (-1.83% 1D, market cap $782.5M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, HELP ranks #359 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HELP carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, COLL (Collegium Pharmaceutical Inc.) holds a B grade (72/100 RQD, P/E 12.4x, ROIC 85.0%, cap $782.3M) and AVBP (ArriVent BioPharma Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $786.5M). Among the 5-stock peer group, COLL leads on earnings multiple (12.4x) while COLL leads on capital efficiency (85.0% ROIC).
For Helus Pharma Inc. (HELP), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #359 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
HELP last traded at $10.71 (-1.83% on volume of 790,395 shares), positioning the stock -10.45% below its 50-day simple moving average ($11.96) and +38.91% above its 200-day simple moving average ($7.71). Across its 52-week range of $3.76 to $15.15, HELP sits at the 61.0% percentile with a 14-day RSI of 44.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.37 to $12.05).
Why HELP Stock slipped -1.83% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.